SCHEMBL30346129

SCHEMBL30346129

CN1CCN(c2ccc(N)cc2-c2cnn(C)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
KDM4E B2RXH2 3/20 0.52
RAD52 P43351 1/20 0.52
AXL P30530 2/20 0.45
ALDH1A1 P00352 3/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LRRK2 Q5S007 1/20 0.42
ADRA2C P18825 3/20 0.42
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
CDC42BPB Q9Y5S2 1/20 0.42
GAA P10253 3/20 0.41
PTK2B Q14289 3/20 0.41
KMT2A Q03164 2/20 0.41
GFER P55789 1/20 0.41
ESR2 Q92731 1/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
NR4A1 P22736 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26091433 1.00 MAPT (0.52) MAPTKDM4ERAD52AXLALDH1A1
SCHEMBL24993092 0.86 GAA (0.51) MAPTAXLLRRK2GAA
SCHEMBL24992450 0.83 ROCK2 (0.42) MAPTKDM4ERAD52LRRK2ROCK2
SCHEMBL29876841 0.81 TYRO3 (0.44) AXLROCK2ROCK1CDC42BPBRET
SCHEMBL328223 0.80 MAPT (0.58) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL26092046 0.78 ALDH1A1 (0.49) KDM4EALDH1A1POLBGAAKMT2A
SCHEMBL30346122 0.78 ALDH1A1 (0.49) KDM4EALDH1A1POLBGAAKMT2A
SCHEMBL28513954 0.78 MAPT (0.39) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL25002870 0.78 CYP3A4 (0.44) ALDH1A1LRRK2RETHRH4
SCHEMBL25001571 0.76 EGFR (0.45) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118891261-A Covalent EGFR inhibitors and methods of use thereof 丹娜-法伯癌症研究院 2024-11-01 CN disclosed
EP-4419529-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2024-08-28 EP disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 WO disclosed